Clique aqui para fazer o download do PDF
Code: 0397
Cell Line: TPC-1
Species: Homo Sapiens
Tissue: Thyroid gland papillary
Morphology: Epithelial
Growth Properties: Adherent
Products: Pax8
Biosafety: 1
Subculturing: Volumes used in this protocol are for 75 cm2 flask; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes. Remove and discard culture medium. Briefly rinse the cell layer with PBS without calcium and magnesium to remove all traces of serum that contains trypsin inhibitor. Add 2.0 to 3.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until the cell layer is dispersed (usually within 5 to 15 minutes). Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal. Add 6.0 to 8.0 mL of complete growth medium and aspirate cells by gently pipetting. Transfer cell suspension to centrifuge tube and spin at approximately 125 x g for 5 to 10 minutes. Discard supernatant and resuspend cells in fresh growth medium. Add appropriate aliquots of cell suspension to new culture vessels. Place culture vessels in incubators at 37°C. NOTE: For more information on enzymatic dissociation and subculturing of cell lines consult Chapter 12 in Culture of Animal Cells, a manual of Basic Technique by R. Ian Freshney, 6th edition, published by Alan R. Liss, N.Y., 2010.
Culture Conditions: Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37°C
Cryopreservation: 95% FBS + 5% DMSO (Dimethyl sulfoxide)
References: PubMed=2823470; DOI=10.1016/0042-6822(87)90171-1 - Tanaka J., Ogura T., Sato H., Hatano M. Establishment and biological characteriz ation of an in vitro human cytomegalovirus latency model. Virology 161:62 -72(1987) PubMed=2516841; DOI=10.1111/j.1349-7006.1989.tb01645.x Ishizaka Y., Itoh F., Tahira T., Ikeda I., Ogura T., Sugimura T., N agao M. Presence of aberrant transcripts of ret proto-oncogene in a human papi llary thyroid carcinoma cell line. Jpn. J. Cancer Res . 80:1149-1152(1989) PubMed=11439348; DOI=10.1038/sj.onc.1204531 Frasca F., Vigneri P., Vella V., Vigneri R., Wang J.Y .J. Tyrosine kinase inhibitor STI571 enhances thyroid ca ncer cell motile response to hepatocyte growth factor. Oncogene 20:3845-3856( 2001) PubMed=17725429; DOI=10.1089/thy.2007.0097 Meireles A.M., Preto A., Rocha A.S., Rebocho A.P ., Maximo V., Pereira-Castro I., Moreira S., Feijao T., Botelho T., Marques R., Trovisco V., Cirnes L., Alves C., Velho S., Soares P., Sobrinho-Simoes M. Molecular and genotypic characteri zation of human thyroid follicular cell carcinomaderived cell lines. Thyroid 17:707-71 5(2007) PubMed=17804723; DOI=10.1158/0008-5472.CAN-06-4026 van Staveren W.C.G., Solis D.W., Delys L., Duprez L., Andry G., Franc B., Thomas G., Libert F., Dumont J.E., Detours V., Maenhaut C. Human thyroid tumor cell lines derived from differen t tumor types present a common dedifferentiated phenotype. Cancer Res. 67:8113-8120( 2007) PubMed=18713817; DOI=10.1210/jc.2008-1102 Schweppe R.E., Klopper J.P., Korch C., Pugazhe nthi U., Benezra M., Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A., Smallridge R.C., Haugen B.R. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer c ell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J. Clin. Endocrinol. Metab. 93:4331-4341(2008) PubMed=19087340; DOI=10.1186/1471-2407-8-371 Ribeiro F.R., Meireles A.M., Rocha A.S., Teixeira M.R . Conventional and molecular cytogenetics of human no n-medullary thyroid carcinoma: characterization of eight cell line models and review of the literature on clinical samples. BMC Can cer 8:371-371(2008) PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690 Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y .C., Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G., Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N. Assembly and initial cha racterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin. Cancer Res. 17:7248-7264(2011) PubMed=22087789; DOI=10.1186/1755-8166-4-26 Maric I., Viaggi S., Caria P., Frau D.V., Degan P., Va nni R. Centrosomal and mitotic abnormalities in cell lines derived from papillary thyroid cancer harboring specific gene alterations. Mol. Cytogenet. 4:26-26(2011) PubMed=23162534; DOI=10.3389/fendo.2012.00133 Saiselet M., Floor S., Tarabichi M., Dom G., Hebrant A ., van Staveren W.C.G., Maenhaut C. Thyroid cance r cell lines: an overview. Front. Endocrinol. 3:133-133(2012) PubMed=23833040; DOI=10.1210/jc.2013-2383 Landa I., Ganly I., Chan T.A., Mitsutake N., Mats use M., Ibrahimpasic T., Ghossein R.A., Fagin J.A. Frequent somat ic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J. Clin. Endocrinol. Metab. 98:E 1562-E1566(2013)
Depositors: Etel Rodrigues Pereira Gimba - Instituto Nacional de Câncer